BioMed Research International / 2015 / Article / Tab 2

Clinical Study

Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets

Table 2

Expression level of microRNAs in both AS and control group validated by real-time PCR.

microRNA
AS group/control group (interval)AS group before/after therapy (interval)

hsa-miR-2021.28 (0.28~5.88)0.50 (0.13~2.08)
hsa-miR-210.51 (0.11~2.5)
hsa-miR-26b**0.70 (0.26~1.89)3.43 (1.20~9.85)
hsa-miR-27a*0.07 (0.01~0.58)0.8 (0.27~2.43)
hsa-miR-29a**0.26 (0.12~0.53)0.35 (0.25~1.24)
hsa-miR-29b**1.22 (0.67~2.22)0.43 (0.19~0.97)
hsa-miR-494**0.58 (0.52–5.6)0.21 (0.05~0.89)
hsa-miR-526a**1.20 (0.48~3.03)0.40 (0.13~1.14)
hsa-miR-98*0.44 (0.10~1.89)
hsa-miR-let7a0.91 (0.16~4.76)
hsa-miR-let7f0.54 (0.11~2.70)
hsa-miR-let7i*,**0.27 (0.05~1.49)0.27 (0.05~1.47)
hsa-miR-126-3p*0.15 (0.03~0.75)0.51 (0.28~0.93)

MicroRNAs had statistically significantly different expression in AS group and healthy control group (fold changes >2, < 0.05).
**Expression levels were changed statistically significantly after medicine treatment (fold changes >2, < 0.05).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.